Repro Net Debt vs Accounts Payable Analysis

KRMD Stock  USD 3.52  0.06  1.68%   
Repro Med financial indicator trend analysis is much more than just breaking down Repro Med Systems prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Repro Med Systems is a good investment. Please check the relationship between Repro Med Net Debt and its Accounts Payable accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Net Debt vs Accounts Payable

Net Debt vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Repro Med Systems Net Debt account and Accounts Payable. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Repro Med's Net Debt and Accounts Payable is -0.51. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Repro Med Systems, assuming nothing else is changed. The correlation between historical values of Repro Med's Net Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Repro Med Systems are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Debt i.e., Repro Med's Net Debt and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.51
Relationship DirectionNegative 
Relationship StrengthVery Weak

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Accounts Payable

An accounting item on the balance sheet that represents Repro Med obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Repro Med Systems are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Repro Med's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Repro Med Systems current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
At present, Repro Med's Enterprise Value is projected to increase significantly based on the last few years of reporting.
 2021 2022 2023 2024 (projected)
Gross Profit13.8M15.4M16.7M17.5M
Total Revenue23.5M27.9M28.5M29.9M

Repro Med fundamental ratios Correlations

0.570.94-0.87-0.470.950.740.40.86-0.40.650.780.650.980.820.550.980.820.790.930.990.630.770.950.70.87
0.570.76-0.1-0.920.310.950.930.71-0.550.370.590.960.440.930.980.410.460.90.480.440.990.610.310.370.57
0.940.76-0.67-0.610.80.90.570.94-0.490.660.80.80.890.940.710.870.830.880.880.890.80.870.80.720.88
-0.87-0.1-0.670.05-0.97-0.310.06-0.60.17-0.56-0.57-0.21-0.91-0.43-0.1-0.95-0.68-0.41-0.82-0.93-0.17-0.51-0.98-0.61-0.69
-0.47-0.92-0.610.05-0.26-0.8-0.89-0.630.64-0.33-0.55-0.91-0.31-0.81-0.97-0.33-0.37-0.84-0.42-0.35-0.91-0.36-0.25-0.28-0.44
0.950.310.8-0.97-0.260.510.150.72-0.280.60.680.410.970.610.310.990.750.590.890.990.380.621.00.650.78
0.740.950.9-0.31-0.80.510.840.82-0.470.480.670.950.640.990.90.60.610.940.650.630.950.80.50.510.75
0.40.930.570.06-0.890.150.840.51-0.450.210.430.90.260.80.910.230.220.790.30.260.910.440.150.180.42
0.860.710.94-0.6-0.630.720.820.51-0.640.710.780.750.780.870.70.790.840.820.860.810.760.760.720.770.83
-0.4-0.55-0.490.170.64-0.28-0.47-0.45-0.64-0.62-0.43-0.5-0.3-0.54-0.64-0.34-0.49-0.43-0.34-0.36-0.64-0.21-0.28-0.65-0.26
0.650.370.66-0.56-0.330.60.480.210.71-0.620.480.380.630.550.380.640.650.410.60.650.470.630.60.970.55
0.780.590.8-0.57-0.550.680.670.430.78-0.430.480.650.740.750.620.740.880.730.750.740.630.530.670.510.62
0.650.960.8-0.21-0.910.410.950.90.75-0.50.380.650.520.940.930.50.480.950.630.530.940.650.410.390.71
0.980.440.89-0.91-0.310.970.640.260.78-0.30.630.740.520.730.40.980.80.660.90.990.50.750.970.690.83
0.820.930.94-0.43-0.810.610.990.80.87-0.540.550.750.940.730.890.690.690.940.730.720.940.80.610.580.78
0.550.980.71-0.1-0.970.310.90.910.7-0.640.380.620.930.40.890.40.490.880.450.420.980.490.310.360.48
0.980.410.87-0.95-0.330.990.60.230.79-0.340.640.740.50.980.690.40.80.670.921.00.470.680.990.690.83
0.820.460.83-0.68-0.370.750.610.220.84-0.490.650.880.480.80.690.490.80.620.770.810.540.640.750.710.62
0.790.90.88-0.41-0.840.590.940.790.82-0.430.410.730.950.660.940.880.670.620.750.690.90.70.590.430.79
0.930.480.88-0.82-0.420.890.650.30.86-0.340.60.750.630.90.730.450.920.770.750.930.510.720.890.660.94
0.990.440.89-0.93-0.350.990.630.260.81-0.360.650.740.530.990.720.421.00.810.690.930.50.710.980.710.84
0.630.990.8-0.17-0.910.380.950.910.76-0.640.470.630.940.50.940.980.470.540.90.510.50.620.380.470.57
0.770.610.87-0.51-0.360.620.80.440.76-0.210.630.530.650.750.80.490.680.640.70.720.710.620.620.680.85
0.950.310.8-0.98-0.251.00.50.150.72-0.280.60.670.410.970.610.310.990.750.590.890.980.380.620.650.78
0.70.370.72-0.61-0.280.650.510.180.77-0.650.970.510.390.690.580.360.690.710.430.660.710.470.680.650.62
0.870.570.88-0.69-0.440.780.750.420.83-0.260.550.620.710.830.780.480.830.620.790.940.840.570.850.780.62
Click cells to compare fundamentals

Repro Med Account Relationship Matchups

Repro Med fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets13.9M39.9M41.3M42.3M28.5M29.9M
Total Current Liabilities2.4M3.7M4.8M7.0M4.5M4.7M
Net Debt(5.5M)(27.1M)(24.7M)(12.5M)(7.0M)(6.7M)
Retained Earnings4.9M3.7M(910.1K)(9.6M)(23.3M)(22.1M)
Cash5.9M27.3M25.3M17.4M11.5M12.1M
Non Current Assets Total2.0M2.4M4.0M12.5M8.2M8.6M
Net Receivables3.2M2.6M4.3M4.5M4.1M4.3M
Common Stock Total Equity422.4K466.8K480.4K488.6K561.9K373.2K
Liabilities And Stockholders Equity13.9M39.9M41.3M42.3M28.5M29.9M
Non Current Liabilities Total239.5K95.6K1.9M4.0M3.7M3.8M
Inventory2.4M6.8M6.1M6.4M3.5M3.7M
Total Liab2.6M3.8M4.8M11.0M8.1M8.5M
Property Plant And Equipment Gross985.6K1.2M1.2M7.7M10.1M10.6M
Total Current Assets11.9M37.5M37.3M29.8M20.3M21.3M
Intangible Assets807.1K843.6K808.8K787.2K754.4K792.1K
Other Current Liab1.7M2.8M5.6M3.7M2.7M2.8M
Total Stockholder Equity11.2M36.2M36.5M31.3M20.4M21.4M
Property Plant And Equipment Net985.6K1.4M1.2M7.7M7.4M7.7M
Accounts Payable572.7K624.9K1.2M2.4M975.2K502.6K
Cash And Short Term Investments5.9M27.3M25.3M17.4M11.5M12.1M
Common Stock Shares Outstanding39.1M41.9M44.4M45.0M45.6M37.4M
Other Current Assets387.4K807.8K3.1M2.9M1.2M1.3M
Other Stockholder Equity5.9M32.0M36.9M40.4M43.2M45.3M
Common Stock422.4K466.8K480.4K488.6K490.9K395.6K
Net Tangible Assets10.4M35.3M35.7M30.5M35.1M19.3M
Other Assets207.8K381.9K2.0M4.1M4.7M4.9M
Capital Surpluse6.3M35.9M40.8M44.3M50.9M53.4M
Property Plant Equipment985.6K1.4M1.2M3.9M4.5M4.7M
Net Invested Capital11.2M36.2M37.0M31.8M20.7M26.7M
Capital Stock422.4K466.8K480.4K488.6K490.9K505.7K
Net Working Capital9.5M33.9M32.5M22.8M15.8M22.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(0.26)
Revenue Per Share
0.674
Quarterly Revenue Growth
0.215
Return On Assets
(0.14)
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.